daraxonrasib · Revolution Medicines · NDA 220910
Rasonque
Earliest generic entry, as listed · earliest of 2 marketed strengths
24 Jan 2042
Blocked by patent: US 12280113.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12280113 | drug substance, drug product · sets the listed date | 24 Jan 2042 |
| US 12403196 | drug substance, drug product | 15 Sep 2041 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 26 Aug 2031 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 220910 · 001 · RLD | tablet, oral | 100MG | 24 Jan 2042 |
| 220910 · 002 · RLD | tablet, oral | 150MG | 24 Jan 2042 |